Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The evolutionarily-conserved La-related protein (LARP) family currently comprises Genuine La, LARP1, LARP1b, LARP4, LARP4b, LARP6 and LARP7. Emerging evidence suggests each LARP has a distinct role in transcription and/or mRNA translation that is attributable to subtle sequence variations within their La modules and specific C-terminal domains. As emerging research uncovers the function of each LARP, it is evident that La, LARP1, LARP6, LARP7 and possibly LARP4a and 4b are dysregulated in cancer. Of these, LARP1 is the first to be demonstrated to drive oncogenesis. Here, we review the role of each LARP and the evidence linking it to malignancy. We discuss a future strategy of targeting members of this protein family as cancer therapy.

Original publication

DOI

10.3390/biom5042701

Type

Journal article

Journal

Biomolecules

Publication Date

16/10/2015

Volume

5

Pages

2701 - 2722

Keywords

LARP, LARP1, RBP, RNA-binding, SS-B, cancer, mRNA, proliferation, transcription, translation, Animals, Autoantigens, Gene Expression Regulation, Neoplastic, Humans, Multigene Family, Neoplasms, Ribonucleoproteins